In this article, we will be taking a look at the 10 best diabetes stocks to buy under $10.
Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration
About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average. Both the number of cases and the prevalence of diabetes have steadily increased during the last several decades. However, according to the International Diabetes Federation, there are currently 500 million people with diabetes globally, and that number is expected to rise by 25% by 2030 and 51% by 2045.
The continuous glucose monitor (CGM) is one type of medical equipment used to help manage diabetes, including type 1 and type 2. It is now a rapidly growing segment of diabetic care devices, and the market has increased significantly in recent years. According to GlobalData, the demand for sophisticated diabetes care products, such as insulin pumps, pens, and continuous glucose monitoring (CGM) devices, was projected to be valued at $21.8 billion in 2023. According to GlobalData’s forecasts, the market will grow at a compound annual growth rate (CAGR) of 6.34% to reach revenues of $33.4 billion by 2030.
There are now 97 goods in the CGM category, according to the GlobalData marketed products database. Only a small number of these devices are implantable sensors; the majority are conventional CGMs. The GlobalData pipeline products database indicates that 133 goods are either approved or in the development stage. According to the data, this market niche is growing rapidly and is a center for cutting-edge new technologies such as implantable CGMs.
AI is now being included in CGM technology. For instance, Roche unveiled Accu-Chek SmartGuide, a revolutionary predictive AI-powered CGM device. Roche Diabetes Care Chief Medical Officer Julien Boisdron described it as “a solution more than a CGM” at the introduction. He explained how the system, which includes a sensor and two algorithms, helps with prediction and data visualization.
Rising Demand for GLP-1 Medications: Opportunities and Challenges in Diabetes and Obesity Treatment
The management of diabetes and its related complications has entered a new era of opportunity. The combined issues of diabetes and obesity can be effectively treated with these innovative approaches. Glucagon-like peptide-1 (GLP-1) agonists are a class of medications used to treat type 2 diabetes mellitus (T2DM) and obesity. The GLP-1 market, which is driven equally by diabetes and obesity, is predicted to reach $100 billion by 2030. By this time, there could be 30 million GLP-1 users or around 9% of the US population.
According to the most recent KFF Health Tracking survey, 12% of adult Americans say they have used a GLP-1 medication at some point. In the past five years, 43% of GLP-1 prescription users had diabetes, and 22% of patients with obesity or overweight diagnoses also took the medication. Over the course of the past year, the percentage of adults who have heard “a little” or “a lot” about these medicines has climbed from 70% to 82%, while the percentage of adults who have heard “a lot” or “a lot” about them has increased from 19% to 32%.
However, the rising demand for these weight-loss and diabetes drugs has created challenges. The National Pharmacy Association (NPA) warned of a possible “explosion in the unlicensed sale of medication online.” Semaglutides, marketed under the name Ozempic, assist people with type 2 diabetes in controlling their blood sugar levels. However, they are also frequently used to aid in weight loss in certain nations, such as the US, where they are marketed under the name Wegovy.
NPA chairman Nick Kaye stated:
“Pharmacists remain deeply concerned that the current medicine shortages crisis could lead to an explosion in the unlicensed sale of medication online.”
Pixabay/Public Domain
Our Methodology
Our methodology involved identifying healthcare companies focused on diabetes treatment using a stock screener. From the resultant dataset, we selected those with stock prices under $10 and ranked them based on their share price as of the close of December 26.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Here is our list of the 10 best diabetes stocks to buy under $10.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) develops and distributes affordable generic and specialty drugs, including key diabetes treatments. Its products include generic metformin, a first-line medication for type 2 diabetes, and recently FDA-approved exenatide, a GLP-1 agonist for managing type 2 diabetes. The company’s focus on complex generics enables cost-effective, advanced treatment options.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) reported strong Q3 2024 results with net revenue of $702 million, a 13% increase from the previous year. Generics revenue grew by 9%, while specialty revenue rose 19%, driven by products in neurology and endocrinology. Adjusted EBITDA was $158 million, up 2%, and adjusted EPS was $0.165. Year-to-date, the company generated $2.68 billion in revenue, driven by strong generics performance, new product launches, and biosimilars. Despite a small GAAP net loss of $0.2 million, the company is focused on high-margin products to improve profitability.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has partnered with Metsera, Inc. to develop next-generation treatments for obesity and metabolic diseases, leveraging its network and facilities to support Metsera’s injectable and oral programs, including GLP-1 and amylin receptor agonists. The company has also resubmitted its New Drug Application for the DHE Autoinjector, plans to launch CREXONT for Parkinson’s disease, and acquired a high-value biosimilar to strengthen its market position. These initiatives, alongside its focus on complex generics and specialty pharmaceuticals, highlight Amneal’s commitment to growth and innovation in the pharmaceutical industry.
Analysts hold a consensus Strong Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), making it one of the best diabetes stocks to watch. As of Q3 2024, 16 hedge funds held shares in the stock, as tracked by the Insider Monkey database. The largest stakeholder in the company was Rubric Capital Management with stakes worth $89.2 million.
MannKind Corporation (NASDAQ:MNKD) develops inhaled therapies for diabetes, with Afrezza as its key product. This rapid-acting inhaled insulin mimics the body’s natural insulin response, working within 12-15 minutes and clearing in 2-3 hours for better blood sugar control. Its small, needle-free inhaler is easy to use, and pre-measured doses ensure accuracy. The company also earns revenue from Afrezza and other diabetes products like the V-Go insulin delivery device.
MannKind Corporation (NASDAQ:MNKD)’s Q3 2024 results highlight strong growth, with $70 million in total revenues, up 37% year-over-year, and $209 million year-to-date, a 49% increase. Net income reached $20 million, with a non-GAAP net income of $45 million, driven by strong Tyvaso DPI sales. The company holds $268 million in cash and investments and is advancing its clinical pipeline.
MannKind Corporation (NASDAQ:MNKD) has made significant strides in its clinical pipeline, expanding the MNKD-101 Phase 3 trial globally and completing the MNKD-201 Phase 1 trial. MNKD-101 also received the FDA Fast Track designation, potentially accelerating its development. The company’s upcoming plans include meeting with the FDA in early 2025 regarding MNKD-2011 and discussing a potential sNDA submission for Afrezza, based on six-month results from the INHALE-1 pediatric diabetes study. The corporation is also advancing two orphan lung programs, with MNKD-201 Phase 1 trial results expected in Q4 2024.
As of Q3 2024, 22 hedge funds held shares in the company, as tracked by the Insider Monkey database. The largest stakeholder was Nitorum Capital with stakes worth $57.6 million. Analysts also hold a consensus Strong Buy rating on the stock.
Evoke Pharma, Inc. (NASDAQ:EVOK) specializes in treatments for gastrointestinal disorders, with a focus on diabetic gastroparesis. Its flagship product, GIMOTI, is the only FDA-approved nasal spray for this condition, offering reliable absorption by bypassing the digestive system—a critical benefit for patients with delayed gastric emptying.
Evoke Pharma, Inc. (NASDAQ:EVOK) reported record Q3 2024 financials with $2.7 million in net product sales, a 70% year-over-year increase, driven by strong demand for GIMOTI. Prescription fills grew 52% year-over-year and 39% since Q1 2024, while cumulative prescriber growth rose 45%. The company reduced its net loss to $1.3 million ($0.94 per share) from $1.7 million ($6.08 per share) in Q3 2023. With $11.3 million in cash as of September 30, 2024, Evoke Pharma, Inc. (NASDAQ:EVOK) has the financial stability to expand GIMOTI’s market presence through Q4 2025.
Evoke Pharma, Inc. (NASDAQ: EVOK) has made notable strides recently, highlighted by real-world data presented at ACG 2024 demonstrating GIMOTI’s effectiveness for GLP-1 therapy patients, positioning it as a strong alternative to oral metoclopramide. A Notice of Allowance from the USPTO further bolstered its intellectual property for GIMOTI. The company raised its 2024 revenue guidance to $9.5-10.0 million and secured $3.5 million in October through warrant exercises, extending its operational runway into Q4 2025 to support GIMOTI’s growth and explore new opportunities.
Evoke Pharma, Inc. (NASDAQ:EVOK)’s innovative approach to tackling diabetic gastroparesis, combined with its strong financial growth, makes it stand out as one of the best diabetes stocks. For investors seeking niche therapies that address critical, unmet needs in diabetes care, the company’s focus on solutions like GIMOTI offers both promise and potential for meaningful impact.
SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company specializing in immunotherapy through its proprietary DiversitAb platform, which produces fully human, high-potency polyclonal antibodies without relying on human donors. The company’s lead asset, SAB-142, targets Type 1 Diabetes (T1D) as a disease-modifying therapy designed to delay the onset and progression of the disease, offering a potential breakthrough over traditional insulin therapies.
The platform’s ability to quickly produce targeted therapies positions SAB Biotherapeutics, Inc. (NASDAQ:SABS) as a leader in multiple therapeutic areas, including infectious diseases and autoimmune disorders. With strong partnerships, government funding, and an innovative approach, the company is poised to address unmet needs in T1D and other diseases, making it an attractive investment opportunity.
SAB Biotherapeutics, Inc. (NASDAQ:SABS) is gaining attention as a top diabetes stock under $10 which was driven by its innovative lead asset, SAB-142, a disease-modifying therapy for Type 1 Diabetes (T1D). SAB-142 has completed Phase 1 enrollment with no serum sickness observed, positioning the company for a Phase 2 study in 2025.
In Q3 2024, the corporation reported a cash position of $30.4 million, R&D expenses of $7.8 million, G&A expenses of $3.5 million, and a net loss of $10.3 million, reflecting increased investment in its pipeline. SAB Biotherapeutics, Inc. (NASDAQ:SABS) presented its clinical progress at the European Association for the Study of Diabetes meeting, with topline Phase 1 data expected by the end of 2024, potentially driving further momentum. Analysts hold a consensus Strong Buy rating on the stock.
Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company developing covalent small molecule drugs to treat genetically defined cancers and metabolic diseases like type 2 diabetes and obesity and it stands sixth on our list among the 10 best diabetes stocks to buy under $10. Its lead product, BMF-219, is a covalent inhibitor of menin, designed to treat both liquid and solid tumors as well as type 2 diabetes. This approach offers greater target selectivity and the potential for more durable therapeutic responses compared to traditional non-covalent drugs.
Biomea Fusion, Inc. (NASDAQ:BMEA) is advancing its diabetes programs with lead candidate icovamenib (BMF-219), currently being tested in the COVALENT-111 (Type 2 diabetes) and COVALENT-112 (Type 1 diabetes) trials. The FDA has lifted the clinical hold on these trials, allowing them to proceed. The company is also developing BMF-650 which is a next-generation GLP-1 receptor agonist for diabetes and obesity. Biomea Fusion, Inc. (NASDAQ:BMEA) expects Phase 2b data for COVALENT-111 and Phase 2a data for COVALENT-112 in December 2024.
For Q3 2024, Biomea Fusion, Inc. (NASDAQ:BMEA) reported a net loss of $32.8 million which is an increase from the previous year. R&D expenses rose to $27.2 million due to clinical trial activities, and G&A expenses increased to $6.8 million. The company’s cash position decreased to $88.3 million, reflecting ongoing investments in research and development.
Analysts have a consensus rating of Strong Buy for the stock. As of Q3 2024, 15 hedge funds owned shares in the company, according to the Insider Monkey database. The largest stakeholder was Cormorant Asset Management, which held $36 million in stakes.
NeuroMetrix, Inc. (NASDAQ:NURO) specializes in non-invasive medical devices focused on neurostimulation and digital medicine, with a primary aim to improve health by managing chronic pain, nerve diseases, and sleep disorders.
NeuroMetrix, Inc. (NASDAQ:NURO) has established itself as a key player in the medical technology sector with innovative solutions like DPNCheck, a diagnostic tool for detecting peripheral neuropathies linked to diabetes, and Quell, a wearable device for chronic pain relief. The company also previously marketed the ADVANCE system for in-office nerve conduction studies. In January 2023, NeuroMetrix launched DPNCheck 2.0, an upgraded version with a touchscreen interface designed for easier use and broader adoption in healthcare settings.
In December 2024, electroCore announced plans to acquire NeuroMetrix, Inc. (NASDAQ:NURO), targeting the Quell platform for treating fibromyalgia and chronic pain, a move that enhances electroCore’s standing in bioelectronic health. Meanwhile, the company continues to expand its Quell Fibromyalgia business through targeted marketing to physicians and sales to VA facilities, reflecting its dedication to advancing non-invasive neurotechnology.
In Q3 2024, NeuroMetrix, Inc. (NASDAQ:NURO) reported a 51% revenue decline to $0.6 million, primarily due to a 58% drop in DPNCheck revenue, which was impacted by challenges in the Medicare Advantage market. DPNCheck, used for diagnosing peripheral neuropathies in diabetes patients, faced significant setbacks. However, revenue from the Quell neurostimulation device rose by 50%, driven by increased sales in Quell Fibromyalgia and Quell Relief. Gross profit decreased to $0.3 million, and operating expenses were reduced by 25% to $2.1 million. The net loss for the quarter was $1.5 million, an improvement from the previous year’s loss. As of September 30, 2024, NeuroMetrix, Inc. (NASDAQ:NURO) had $14.8 million in cash and cash equivalents.
Fractyl Health, Inc. (NASDAQ:GUTS) is a company dedicated to transforming the treatment of type 2 diabetes (T2D) and obesity by developing therapies that address the root causes of these metabolic diseases rather than just managing symptoms. Its key products include the Revita DMR System which is a minimally invasive therapy that uses a balloon catheter to regenerate the duodenum and combat dysfunction linked to high-fat, high-sugar diets, and Rejuva, a gene therapy platform designed to modify pancreatic islet cells and enable long-term remission of T2D and obesity by improving metabolic hormone function.
Fractyl Health, Inc. (NASDAQ:GUTS)’s Q3 2024 financial report highlights stable revenue from its pilot commercial launch in Germany, with increased expenses reflecting progress in clinical and development programs. R&D costs rose to $19.0 million which was driven by advancements in the REMAIN-1 and REVITALIZE-1 trials and the Rejuva program. SG&A expenses increased to $4.8 million due to personnel costs and professional services. The company reported a net loss of $23.2 million, up from $15.7 million in Q3 2023, mainly due to higher operating expenses and non-cash losses from notes payable valuation changes.
The corporation maintains a strong cash position of $84.7 million as of September 30, 2024, expected to sustain operations into Q4 2025. Key milestones include mid-point data from REMAIN-1 in Q2 2025 and topline results from REVITALIZE-1 in mid-2025. Regulatory achievements, such as the CE mark in Germany and FDA Breakthrough Device Designation, bolster its market potential. Investors remain optimistic about its innovative therapies and forthcoming clinical data.
Fractyl Health, Inc. (NASDAQ:GUTS) presented promising weight maintenance and metabolic benefit data for Revita and Rejuva at ObesityWeek 2024. Additionally, the company is enrolling patients in its German Real-World Registry Study, with new data expected in Q1 2025 to further validate Revita’s clinical potential.
Standing third on our list is Applied Therapeutics, Inc. (NASDAQ:APLT). It is a biopharmaceutical company focused on developing treatments for rare diseases, particularly those related to metabolic disorders. Its lead drug, govorestat (AT-007), targets Aldose Reductase Inhibitors (ARIs) to treat conditions like Galactosemia, SORD Deficiency, and PMM2-CDG. The company is also developing AT-001 for Diabetic Cardiomyopathy and Diabetic Peripheral Neuropathy, and AT-003 for Diabetic Retinopathy, addressing significant unmet needs in diabetes care.
Applied Therapeutics, Inc. (NASDAQ:APLT) reported $122,000 in revenue for Q3 2024 which is a significant decrease from $10.66 million in the same period of 2023 due to a one-time licensing agreement. R&D expenses rose to $14.8 million which was driven by increased personnel costs and data storage for commercialization. G&A expenses increased to $15.0 million due to higher headcount. The net loss for Q3 was $68.6 million, compared to $42.4 million in Q3 2023, largely due to higher expenses and changes in warrant liabilities.
As of September 30, 2024, the company had $98.9 million in cash, with a runway expected to last until 2026. Applied Therapeutics, Inc. (NASDAQ:APLT) is awaiting critical regulatory decisions, including the FDA’s Priority Review for govorestat in Classic Galactosemia, with a PDUFA date of November 28, 2024, and an EMA decision expected in Q1 2025. An NDA submission for govorestat in SORD Deficiency is planned for early Q1 2025.
Analysts hold a consensus Moderate Buy rating on the stock. The average price target for the stock is $4.50, with a high estimate of $8.00 and a low estimate of $1.50. The average price target indicates a 411.31% increase from the last price of $0.88.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company leveraging advanced genetic research to develop transformative medicines, particularly for diabetes and related conditions. Its flagship drug, INPEFA (sotagliflozin), is an oral therapy targeting heart failure, type 1 and type 2 diabetes, and cardiovascular risks.
In Q3 2024, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported $1.7 million in net sales for INPEFA (sotagliflozin), with year-to-date sales reaching $4.5 million. Growth was driven by increased prescribing, despite a reduced sales force. The company focuses on advancing ZYNQUISTA (sotagliflozin) for type 1 diabetes (T1D) and chronic kidney disease (CKD). An FDA advisory committee recently reviewed its application, expressing significant support for its use in patients aged 60-90, with a PDUFA goal date of December 20, 2024. If approved, ZYNQUISTA would be the first adjunct to insulin for glycemic control in T1D.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has entered an exclusive licensing agreement with Viatris for sotagliflozin outside the U.S. and Europe, involving a $25 million upfront payment and up to $197 million in regulatory and sales milestones. The LX9211 program for diabetic neuropathic pain has completed enrollment screening for its Phase 2b PROGRESS study, with topline data expected in Q1 2025. Additionally, the corporation is advancing the SONATA HCM Phase 3 trial and developing LX9851 for obesity, diversifying its pipeline beyond INPEFA and addressing unmet medical needs in diabetes and related conditions.
Analysts have given the stock a consensus rating of “Strong Buy,” with an average price target of $4.30. Forecasts range from a low of $1.20 to a high of $10.00, reflecting a potential 501.65% increase from its most recent price of $0.78.
Senseonics Holdings, Inc. (NYSE:SENS) tops the list for being one of the best diabetes stocks. It develops implantable continuous glucose monitoring (CGM) systems for diabetes management. Its flagship products, including Eversense, Eversense XL, and Eversense 365, feature a sensor implanted under the skin, a rechargeable transmitter, and a mobile app for real-time glucose tracking. The Eversense 365 stands out as the world’s first year-long CGM system.
In Q3 2024, Senseonics Holdings, Inc. (NYSE:SENS) achieved key milestones, including FDA approval and the launch of the Eversense 365, a 365-day CGM system, with Ascensia Diabetes Care leading commercialization and Mercy Health System performing the first patient insertion. Revenue was $4.3 million, down from $6.1 million in Q3 2023, due to inventory transitions to Eversense 365.
Senseonics Holdings, Inc. (NYSE:SENS) reported a $4.1 million gross loss from $4.8 million in one-time transition charges, while operating expenses rose to $8.3 million, and R&D expenses decreased to $10.5 million. Net loss remained at $24.0 million ($0.04 per share), similar to Q3 2023, bolstered by $20 million in equity offerings and a post-quarter $16 million financing, bringing its cash position to $74.8 million with $55.9 million in debt.
Senseonics Holdings, Inc. (NYSE:SENS) has seen promising results following the Eversense 365 launch, including doubling Direct-to-Consumer leads in October and November, achieving record new patient shipments, and a 42% increase in prescribing providers. Prescriptions from top prescribers rose by 69%, with one-third being first-time users. The company plans to double U.S. patient starts and grow its global base by 50% in 2024, focusing on product development, pump connectivity, healthcare partnerships, and the international launch of Eversense 365. A reverse stock split is planned for January 2025 to attract institutional investors.
Overall, Senseonics Holdings, Inc. (NYSE:SENS) ranks first among the 10 best diabetes stocks to buy under $10. While we acknowledge the potential of healthcare companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than SENS but that trades at less than 5 times its earnings, check out our report about thecheapest AI stock.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Subscribe to Insider Monkey's Free Daily Newsletter and Join 100K+ Readers
Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!
It’s the revolution reshaping every industry on the planet.
From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.
Here’s why this is the prime moment to jump on the AI bandwagon:
Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.
Imagine every sector, from healthcare to finance, infused with superhuman intelligence.
We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.
This isn’t a maybe – it’s an inevitability.
Early investors will be the ones positioned to ride the wave of this technological tsunami.
Ground Floor Opportunity: Remember the early days of the internet?
Those who saw the potential of tech giants back then are sitting pretty today.
AI is at a similar inflection point.
We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.
This is your chance to get in before the rockets take off!
Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.
AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.
The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.
As an investor, you want to be on the side of the winners, and AI is the winning ticket.
The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.
From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.
This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.
By investing in AI, you’re essentially backing the future.
The future is powered by artificial intelligence, and the time to invest is NOW.
Don’t be a spectator in this technological revolution.
Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.
This isn’t just about making money – it’s about being part of the future.
So, buckle up and get ready for the ride of your investment life!
Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)
The AI revolution is upon us, and savvy investors stand to make a fortune.
But with so many choices, how do you find the hidden gem – the company poised for explosive growth?
That’s where our expertise comes in.
We’ve got the answer, but there’s a twist…
Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.
That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!
Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.
This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.
It’s like having a race car on a go-kart track.
They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.
Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.
We want to make sure none of our valued readers miss out on this groundbreaking opportunity!
That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.
For a ridiculously low price of just $29.99, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!
Here’s why this is a deal you can’t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.99.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!
I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.
We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…
Should I put my money in Artificial Intelligence?
Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.
Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…
But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.
That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…
And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.
He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.
